SCHEDULE 13G: Bleichroeder Entities Disclose 9.9% Passive Stake in Curis Inc.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have disclosed a passive beneficial ownership of 9.9% of Curis Inc.'s common shares as of March 31, 2025.

Summary

• The filing identifies Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach as the reporting persons.
• The issuer is Curis Inc., with its common shares (CUSIP 231269309) being the subject of the filing.
• As of March 31, 2025, the reporting persons beneficially own an aggregate of 1,035,662 common shares of Curis Inc.
• This beneficial ownership represents 9.9% of the outstanding class of common shares.
• The reporting persons hold sole voting power and sole dispositive power over all 1,035,662 shares.
• The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Notably, if not for a 9.99% exercise limit on certain warrants and pre-funded warrants, Bleichroeder would be deemed to beneficially own 3,509,640 Common Shares, which would represent 32% of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable investment entity like Bleichroeder is generally viewed positively, as it indicates investor confidence. The potential for a much larger stake (32%) if not for warrant limits adds to the positive sentiment, suggesting strong underlying interest.

Positives

• A significant institutional investor, Bleichroeder LP, along with its affiliates, has taken a substantial passive stake in Curis Inc., potentially signaling confidence in the company's long-term prospects.
• The beneficial ownership of 9.9% indicates a notable commitment from the reporting entities.
• The disclosure of potential ownership of 32% if not for warrant exercise limits suggests a deeper underlying interest or potential future stake in the company.

Negatives

• The filing itself, being a passive Schedule 13G, does not inherently contain negative information about the company's operations or financial performance.
• The 9.99% exercise limit on warrants and pre-funded warrants prevents the reporting persons from immediately holding a larger, potentially more influential, stake of 32%.

Industry Context

Curis Inc. operates in the biotechnology and pharmaceutical sector, focusing on developing innovative therapies. The entry of a significant passive investor like Bleichroeder could be seen as a vote of confidence in the company's drug pipeline or market position within this competitive industry.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a positive signal, potentially increasing investor confidence and liquidity for Curis Inc. common shares.

Key Dates

Keywords

Curis Inc., Bleichroeder LP, Bleichroeder Holdings LLC, Andrew Gundlach, Schedule 13G, Common Shares, Beneficial Ownership, Passive Investment, SEC Filing, Institutional Investor, Biotechnology, Pharmaceuticals